INTRODUCTION: @entity5 angiogenesis via @entity7 ( @entity7 ) is essential for promoting @entity5 progression and is overexpressed in @entity14 . The humanised monoclonal anti- @entity7 antibody bevacizumab (Avastin  , Genentech Inc., South San Francisco, CA) has shown activity in metastatic @entity14 (mCRC) combined with conventional chemotherapy. The search for biomarkers to predict response to anti-angiogenic therapy in mCRC is of great interest. We investigated several potential predictive anti-angiogenic markers including circulating endothelial progenitor cells (EPC) in @entity1 with mCRC receiving bevacizumab containing treatment within a randomised multicenter phase 2 study of the German @entity5 study group. METHODS: We collected sequential blood samples and @entity5 tissues from @entity1 participating in a clinical trial for @entity1 with mCRC. We performed flow cytometry of mononuclear cells isolated from peripheral blood to assess CD 133 + or @entity2280 + / @entity319 + EPC before the first bevacizumab containing chemotherapy and after 21 days. Circulating @entity7 blood levels before a bevacizumab containing chemotherapy regimen and after 21 days and @entity7 expression in @entity5 tissue were examined. RESULTS: @entity1 with mCRC and a partial remission after six months of immuno-chemotherapy containing bevacizumab showed a reduction of @entity2280 negative @entity319 positive cells as early as 3 weeks after start of therapy. In contrast, no remarkable change in the number of @entity2280 / @entity319 positive or @entity2280 / @entity5439 positive cells was seen. Furthermore, there was no correlation between treatment response and @entity7 expression within the @entity5 tissue. The mAb bevacizumab reduced serum- @entity7 levels in @entity1 independent of their treatment response to bevacizumab. DISCUSSION: We examined circulating endothelial progenitor cells (EPC), serum- @entity7 levels and the @entity5 tissue @entity7 expression of @entity1 with mCRC under a bevacizumab containing chemotherapy. The @entity1 with a partial remission after six months of immuno-chemotherapy showed a reduction of @entity2280 negative @entity319 positive cells as early as 3 weeks after start of therapy. Neither serum nor tissue markers were of significant predictive value in our pilot study. Furthermore, we review the current data on biomarkers for anti-angiogenic therapy of mCRC.

Biomarkers of anti-angiogenic therapy in metastatic XXXX (mCRC): original data and review of the literature.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5439 :: ('8842', 'Gene') :: ['CD133'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['AIO GI tumour', 'Tumour', 'tumour'] @entity319 :: ('3791', 'Gene') :: ['KDR'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity2280 :: ('947', 'Gene') :: ['CD 34']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
